 Eli Lilly said on Monday a trial of its experimental Alzheimers drug donanemab showed it slowed by about a third the rate of decline in a combined measure of cognition and function in early-stage victims of the disease. Eli Lilly CEO David Ricks joined Squawk Box on Tuesday to discuss the positive data. 